caa a22 4500 465735800 CHVBK 20180323111754.0 cr unu---uuuuu 170327e19900401xx s 000 0 eng 10.1007/BF00177842 doi (NATIONALLICENCE)springer-10.1007/BF00177842 Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes [Elektronische Daten] A review of pre-clinical and clinical investigations [Randall Merchant, Mary Ellison, Harold Young] Summary: Over the past few years, we and a number of other groups have conducted laboratory experiments and clinical trials of human recombinant interleukin-2 (rIL-2) alone or in combination with autologous ‘activated' lymphocytes expressing in vitro tumoricidal activity in order to define toxicity and indicate its potential efficacy in patients with high-grade glioma. Because high rIL-2 concentrations can be attained with considerably less toxicity than with a systemic approach, all of the clinical trials, to date, have chosen a direct route; injecting lymphokine and cells into tumor tissue, the cystic cavity remaining after tumor excision, and/or neural parenchyma surrounding the site of tumor excision. While the rIL-2 therapies, as they have been applied in animal glioma models and patients, are safe, cerebral edema around the site of treatment has been a consistent finding. We have also seen, however, that steroid medications used by patients to control their cerebral edema may depress the anti-tumor activity of rIL-2 by depressing the capacity of lymphocytes to develop normal LAK activity. Although none of the immunotherapies involving rIL-2 have produced cures, the fact that sustained clinical responses have been reported, suggests that such therapies may slow a recurrence of tumor at the site of treatment. Efforts to improve outcome from rIL-2 - based immunotherapies for malignant glioma are continuing with manipulation of rIL-2 dosing and scheduling and also with combinations of rIL-2 and other recombinant cytokines. Kluwer Academic Publishers, 1990 interleukin-2 nationallicence glioma nationallicence lymphokines nationallicence brain nationallicence toxicity nationallicence immunotherapy nationallicence Merchant Randall Department of Anatomy, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA aut Ellison Mary Department of Neurosurgery, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA aut Young Harold Department of Surgery, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 8/2(1990-04-01), 173-188 0167-594X 8:2<173 1990 8 11060 https://doi.org/10.1007/BF00177842 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177842 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Merchant Randall Department of Anatomy, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA aut NATIONALLICENCE 700 1- Ellison Mary Department of Neurosurgery, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA aut NATIONALLICENCE 700 1- Young Harold Department of Surgery, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 8/2(1990-04-01), 173-188 0167-594X 8:2<173 1990 8 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer